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ARTICLE

OPEN

Whole-genome sequencing expands diagnostic utility and
improves clinical management in paediatric medicine
Dimitri J Stavropoulos1,2, Daniele Merico3,4, Rebekah Jobling5, Sarah Bowdin5,6,7, Nasim Monfared5,6, Bhooma Thiruvahindrapuram3,4,
Thomas Nalpathamkalam3,4, Giovanna Pellecchia3,4, Ryan KC Yuen3,4, Michael J Szego3,8,9, Robin Z Hayeems10, Randi Zlotnik Shaul8,11,
Michael Brudno4,12,13, Marta Girdea4,12, Brendan Frey13,14,15, Babak Alipanahi14, Sohnee Ahmed5, Riyana Babul-Hirji4,5,15,
Ramses Badilla Porras5, Melissa T Carter5,7, Lauren Chad5, Ayeshah Chaudhry5, David Chitayat5,7,16, Soghra Jougheh Doust5,
Cheryl Cytrynbaum4,5,15, Lucie Dupuis5,15, Resham Ejaz5, Leona Fishman5, Andrea Guerin5, Bita Hashemi5, Mayada Helal5,
Stacy Hewson5,15, Michal Inbar-Feigenberg5, Peter Kannu4,5,7, Natalya Karp5, Raymond H Kim5, Jonathan Kronick5, Eriskay Liston17,
Heather MacDonald18, Saadet Mercimek-Mahmutoglu4,5,7, Roberto Mendoza-Londono4,5,7, Enas Nasr5, Graeme Nimmo5,
Nicole Parkinson17, Nada Quercia5,15, Julian Raiman5,7, Maian Roifman5, Andreas Schulze4,5,7, Andrea Shugar5,15, Cheryl Shuman5,15,
Pierre Sinajon5, Komudi Siriwardena5,7, Rosanna Weksberg4,5,7,15, Grace Yoon5,7, Chris Carew6, Raith Erickson19, Richard A Leach19,
Robert Klein19, Peter N Ray1,4,6,15, M Stephen Meyn4,5,6,15,20, Stephen W Scherer3,4,6,15,20, Ronald D Cohn4,5,6,7,20 and
Christian R Marshall1,6,20
The standard of care for ﬁrst-tier clinical investigation of the aetiology of congenital malformations and neurodevelopmental
disorders is chromosome microarray analysis (CMA) for copy-number variations (CNVs), often followed by gene(s)-speciﬁc
sequencing searching for smaller insertion–deletions (indels) and single-nucleotide variant (SNV) mutations. Whole-genome
sequencing (WGS) has the potential to capture all classes of genetic variation in one experiment; however, the diagnostic yield for
mutation detection of WGS compared to CMA, and other tests, needs to be established. In a prospective study we utilised WGS and
comprehensive medical annotation to assess 100 patients referred to a paediatric genetics service and compared the diagnostic
yield versus standard genetic testing. WGS identiﬁed genetic variants meeting clinical diagnostic criteria in 34% of cases,
representing a fourfold increase in diagnostic rate over CMA (8%; P value = 1.42E − 05) alone and more than twofold increase in
CMA plus targeted gene sequencing (13%; P value = 0.0009). WGS identiﬁed all rare clinically signiﬁcant CNVs that were detected by
CMA. In 26 patients, WGS revealed indel and missense mutations presenting in a dominant (63%) or a recessive (37%) manner. We
found four subjects with mutations in at least two genes associated with distinct genetic disorders, including two cases harbouring
a pathogenic CNV and SNV. When considering medically actionable secondary ﬁndings in addition to primary WGS ﬁndings, 38% of
patients would beneﬁt from genetic counselling. Clinical implementation of WGS as a primary test will provide a higher diagnostic
yield than conventional genetic testing and potentially reduce the time required to reach a genetic diagnosis.
npj Genomic Medicine (2016) 1, 15012; doi:10.1038/npjgenmed.2015.12; published online 13 January 2016

INTRODUCTION
Congenital anomalies are a leading cause of infant mortality, and
developmental disabilities have profound adverse effects on
children, their families, health care systems and societies.1
Collectively, children with these disorders comprise 5–10% of
the general population2 and encompass the largest group referred
for genetic evaluation. These numbers are signiﬁcant given that
50–80% of the resources used to manage diseases in full-service

paediatric inpatient facilities have a recognised genetic
component.3,4
The ability to provide optimal clinical management for these
individuals is dependent on identifying the underlying genetic
cause in order to determine prognosis, guide treatment and
institute appropriate surveillance and prevention programmes.5
However, it is often difﬁcult to achieve a deﬁnitive genetic
diagnosis, for example, in children with developmental delay,
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autism and/or congenital anomalies because their phenotypic
features are often nonspeciﬁc and the differential diagnosis can
include hundreds of rare genetic disorders.3,4
The development of chromosome microarray analysis (CMA)
revealed that copy-number variation (CNV) is a major aetiology
for congenital malformations and neurodevelopmental delay.
CMA has now become the ﬁrst-line diagnostic test for these
disorders, achieving greater than a twofold increase in diagnostic
yield compared with G-band karyotype analysis.6,7 Despite these
successes, 80–85% of patients do not reach a diagnosis by CMA.7
Consequently, physicians often supplement CMA with targeted
testing by sequence analysis of known disease-associated genes
or gene panels. This hypothesis-driven approach, which relies on
the ability to recognise the most likely disorder associated with
the presenting symptoms, often fails to reach a diagnosis.
Recent improvement in cost and accuracy of whole-exome
sequencing (WES) has made it feasible to investigate all known
coding genes for sequence-level mutations. Current estimates
show clinical WES provides a diagnostic yield of ~ 25% for
patients affected with neurological disorders and/or congenital
anomalies.8,9 Although larger clinically relevant CNVs may be
detected through WES,10 the lack of sensitivity and reliability to
detect smaller CNVs (o 100 kb) and insertion–deletions (indels),
as well as complex structural variations (SVs) has precluded
its implementation as a single clinical test able to capture all
potential disease-causing genetic variants.8,9 As such, sequential
testing using CMA, WES or targeted gene-based testing often
occurs.
Whole-genome sequencing (WGS) has the potential to identify
nearly all forms of genetic variation.11 Several studies have
demonstrated the advantages of WGS for mutation detection12–15
and WGS analyses of paediatric populations has shown
identiﬁcation of clinically relevant variants in ~ 40% of those with
autism15 and ~ 60% of those with intellectual disability.16,17 These
observations indicate that WGS is poised to have tremendous
impact for paediatric patients where CMA is currently a standard
ﬁrst-line diagnostic evaluation. However, challenges such as cost,
processing, clinical interpretation and storage of vast amounts
of data exist18 and evidence is required to demonstrate the
diagnostic utility of WGS.19 Here we performed WGS on 100
consecutive children referred for CMA by clinical geneticists and
examined the diagnostic yield of WGS compared with conventional molecular testing.
RESULTS
Cohort enrolment and description
We recruited 100 consecutive paediatric patients (57% males)
o18 years of age (mean 5.5 years; Supplementary Table 1) who
met criteria for CMA, and WGS was offered in parallel with clinical
CMA testing. These 100 cases came from 201 families that were
approached (95 declining participation and 6 undecided). Eight
percent of families reported consanguinity. Of those families that
enroled, 26% opted out of receiving information about secondary
ﬁndings related to medically actionable adult onset disorders.20,21
Patients displayed a wide array of symptoms described by 453
unique HPO terms across the cohort, with 57% having at least one
term associated with developmental delay (Supplementary
Table 2; Supplementary Figures 2 and 3). The most commonly
observed phenotypes were abnormalities of the nervous system
(77%), skeletal system (68%), growth (44%), eye (34%), cardiovascular (32%) and musculature (27%; Supplementary Table 3).
Aside from CMA, an average of two additional genetic diagnostic
tests were ordered at the time of WGS analysis (Range 1–13 tests;
Supplementary Table 4).
npj Genomic Medicine (2016) 15012

Whole-genome sequencing
WGS yielded an average depth coverage of 51.8 × with 99% of the
mapped sequence at 410-fold representation (Supplementary
Table 5). Different WGS technologies will vary in the number of
variants identiﬁed. The WGS platform used in this study generated
a total of 3.3 to 4.3 million high-quality variants per sample.
On average, WGS identiﬁed 43.5 million SNVs, 248 CNVs using
read depth method and 1,604 structural variations (tandem
duplications and deletions) using abnormal junction and
discordant mate-pair clusters (Supplementary Methods and
Supplementary Tables 6 and 7). Filtering for coding variants, we
detected an average of 20,014 exonic and splicing variants per
individual. As expected, CNVs identiﬁed by read depth (median
size 10 kb) were larger than the SVs detected by split read or
mate-pair mapping (median size 495 bp). Approximately 28% of
the CNVs and 2.0% of the SVs impacted gene coding exons. WGS
data are deposited in the European Genome-phenome Archive
(www.ebi.ac.uk/ega/) under accession number EGAS00001001623.
Variant analysis and molecular diagnosis using WGS
We developed a pipeline to prioritise WGS variants (SNVs and
Indels) of clinical signiﬁcance, interrogating on average 498 rare
damaging events per genome parsed into categories based on
mode of inheritance (Supplementary Methods and Supplementary
Figure 1). Rare CNVs and SVs were analysed for pathogenicity
according to established methods22,23 and candidates were
discussed with the referring clinician to assess whether the
variant(s) were pathogenic or related to the phenotype and
therefore considered to be clinically relevant.
Overall, we identiﬁed and returned 38 variants that were related
to the primary indication providing a molecular diagnosis for 34
individuals (34%; 95% conﬁdence interval (CI) 25–44%) (Table 1).
Of the positive diagnoses, 8 (8%) individuals harboured a
pathogenic CNV (Table 2), whereas 28 (28%) carried sequencelevel variants that were diagnostic (Table 3). The majority
of sequence-level variants were autosomal dominant (63%)
compared to recessive (37%) with no X-linked forms found. All
pathogenic CNVs detected by WGS were conﬁrmed with CMA and
Table 1. Molecular diagnosis rates by genetic type and mode of
inheritance
Whole-genome
sequencing

Undiagnosed
Diagnosis
Multiple molecular
diagnosisa
Type of genetic change
CNV only
SNV only
CNV and SNV
Mode of Inheritance
Autosomal
Dominant
Autosomal Recessive
Dominant and
Recessive

Clinical testing
CMA only

All genetic
tests

66
34
4

92
8*
0

87
13**
1

6
26
2

8
—
—

7
5
1

24

8

3

9
1

0
0

3
0

Abbreviations: CNV, copy-number variants; SNV, single-nucleotide variant.
a
A total of four cases had two distinct molecular diagnosis including two
patients had a pathogenic CNV and SNV (see Tables 2 and 3). χ2 proportion
test *P = 1.42E − 05 and **P = 0.0009.
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Table 2.
Case
ID

Clinically signiﬁcant copy-number variants identiﬁed by chromosomal microarray and whole-genome sequencing
Sex Clinical microarray

Size
(Kb)

Origina Diagnosis and managementb

WGS read depth CNV

1090 F

ChrX:60,701–91,873,056 del

91,813 ChrX:176,00–91,866,000 del

1005c M
1034 F

ChrX:91,877,172–155,174,078 dup 63,297 ChrX:92,796,000–155,260,560 dup
Chr4:33,574–7,608,090 del
7,575 Chr4:68,000–7,616,000 del
DN
Chr22:18,713,432–21,440,515 del 2,727 Chr22:18,888,000–21,466,000 del DN

1022 F

Chr10:30,822,400–32,872,626 del

2,050 Chr10:30,814,000–32,892,000 del

DN

1026 M
1066 M

Chr22:35,931,002–37,272,620 del
Chr8:97,145,564–98,301,541 del

1,342 Chr22:35,890,000–37,302,000 del
1,156 Chr8:97,134,000–98,308,000 del

N/A
DN

1027 F
1102 M

Chr16:15,507,164–16,400,833 del
Chr2:51,021,507–51,358,841del

894
337

Chr16:15,480,000–16,296,000 del
Chr2:51,020,000–51,374,000 del

DN

DN
DN

Partial genetic diagnosis. Category 1. Turner
syndrome but hydrocephalus is not explained
by molecular ﬁnding.
Category 1. Wolf–Hirschhorn syndrome.
Category 1. 22q11.2 deletion syndrome,
referred to specialized clinic.
Category 2. 10p11.23-p11.2 deletion. ZEB1;
corneal dystrophy, maldevelopment of the
corpus callosum.
Category 3. 1.34-Mb deletion in 22q12.3.
Complex phenotype with two genetic disorders.
Category 2. 8q22.1 de novo deletion. Patient also
has paternally inherited CCM2 pathogenic
variant c.1054delG (p.Gly352Val*2) related to
Cerebral cavernous malformation (CCM)
diagnosis (Table 3).
Category 2. 16p13.11 deletion.
Complex phenotype with two genetic disorders.
Category 2. Pathogenic 2p16.3 microdeletion
overlapping NRXN1 gene associated with global
developmental delay and Autism Spectrum
disorder but not able to explain episodic
hypotonia and developmental regression
history. Pathogenic ATP1A3 variant c.2452G4A
(p.Glu818Lys) associated with CAPOS Syndrome
explains this phenotype (Table 3).

Abbreviations: DN, de novo; F, female; M, male; N/A, not available.
a
Origin of TransmiAssion: DN; N/A.
b
All ﬁndings were relevant to Genetic counselling and were further split into categories based on clinical management: Category 1 (Disease-speciﬁc published
management guidelines), Category 2 (Management based on case reports or known function of genes), and Category 3 (No management change).
c
In some cases the WGS CNVs were fragments and had to be manually resolved (see Supplementary Figure 8 for example in case 1005).

all diagnostic sequence-level variants were conﬁrmed with Sanger
sequencing. The diagnostic rate for those with developmental
delay was higher than average 38.6% (22/57) and was lowest
(15.3%) in those presenting with connective tissue disorders
(Supplementary Figure 4 and Supplementary Figure 5). Combining
CNVs and SNVs, we conﬁrmed de novo disease-causing variants in
15% of this case cohort.
We observed that 4% of cases had pathogenic variants at two
distinct disease loci leading to a composite phenotype.8,9 This is
likely an underestimate given that in several patients the
diagnostic ﬁndings only explained part of the clinical features
(see patients (1006, 1040, 1062, 1070, 1090 in Tables 2 and 3).
Interestingly, two of our patients harboured a pathogenic CNV and
SNV (1066 and 1102 in Table 2). For several cases, the genomic
diagnosis impacted clinical management and the identiﬁcation of
at-risk relatives (see Table 3 and Supplementary Table 8 for patient
case examples).
Secondary ﬁndings
Although our focus was the investigation of the diagnostic yield of
WGS for the primary presenting clinical symptoms, we also
examined the 56 genes listed in the 2013 American College of
Medical Genetics and Genomics (ACMG) published guidelines for
incidental ﬁndings20 and identiﬁed 7 variants as potentially
medically actionable and appropriate for return (Table 4). Three
of these seven patients (1027, 1040, and 1078) also had primary
diagnostic variants.
Comparison of CNV calling from WGS versus CMA
An important consideration in the evaluation of WGS as a clinical
test is the sensitivity in detecting clinically relevant CNVs.

We examined the characteristics of CNVs detected by WGS and
CMA (Supplementary Table 7 and Supplementary Figure 7). CMA
identiﬁed an average of six CNVs per patient including nine
pathogenic CNVs in eight individuals (ranging in size from 337 kb
to 92 Mb). All of the reported pathogenic changes were detected
by WGS (Table 2). We evaluated concordance of the results
obtained from the clinical microarray analysis with CNVs obtained
from the WGS. CMA detected a total of 578 variants, of which 52%
were detected by WGS consistent with published ﬁndings.17,24
The WGS data afforded several advantages over CMA for CNV
detection. First, the resolution of WGS is greater than CMA,
typically detecting 41,500 unbalanced changes that cannot be
found using CMA. The majority of these are small and intergenic
but many impact exons and may therefore be medically relevant.
Although we did not ﬁnd a plausible diagnosis from one of the
variants beyond the resolution of CMA, we did detect carriers
with clinically relevant exonic deletions in genes associated with
autosomal recessive disorders (e.g., deletion of exons 7–8 of CLN3;
neuronal ceroid lipofuscinosis-3; Supplementary Table 9). An
additional advantage of WGS is demonstrated by using paired-end
sequencing to obtain breakpoint resolution and allele speciﬁc
CNVs. For example, both the WGS read depth and CMA detected a
300-kb duplication of uncertain signiﬁcance (VUS) at 9p24.3 in one
patient, but split read mapping revealed it to be a 503,479-bp
tandem duplication on one allele overlapping a 235,071-bp
deletion on the other allele (data not shown).
Comparison of diagnostic yield of WGS versus CMA and standard
genetic testing
The total diagnostic rate from standard testing (CMA plus targeted
gene sequencing) was less than half of WGS (13% vs. 34%;
P value = 0.0009; Table 1). Of the targeted sequence tests ordered,
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F

M
M

M

M

M
F

F

F

F

M

M

F

M

F
F

M

M
M

F

M

M

M
F

M

F

F
F

1004

1006
1008

1009

1012

1015
1016

1023

1029

1032

1040

1045

1049

1050

1055
1057

1059

1062
1066

1070

1078

1080

1089
1093

1102

1103

1107
1108

SMARCA2
ALDH18A1

VPS53

AD
AR

AR

AD

AR

COG5

ATP1A3

AR
AR

AD
AD

MC4R
COL4A1

PLVAP
NGLY1

AR

AD

AR
AD

AD

AD
AD

AD

AD

AR

AD

AD

AD

AR

AD
AR

AD

AR

AD
AD

AD

IP

TYR

VWF

GJB2
CCM2

PIK3R1

PACS1
SETD5

CBL

NSD1

TSEN54

EXT2

SPTAN1

PIK3R2

NGLY1

GDF5
PANK2

KAT6B

LARP7

MC4R
SMARCB1

EP300

Gene

c.1429C4T (p.Arg477*) (het)/
c.1716T4G (p.Ser572Arg)
(het)
c.2639 C4T (p.Thr880Ile) (het)
c.1321C4T (p.Arg441*)/
c.191G4A (p.Arg64His) (het)

c.1072C4T (p.Arg358*) (hom)
c.517A4G (p.Arg173Gly)
(hom)
c.1205C4T (p.Ser402Leu)
(hom)
c.2452G4A (p.Glu818Lys)
(het)

c.607C4T (p.Arg203Trp) (het)
c.1576_1580del
(p.Glu526Lysfs*15) (het)
c.1993G4A (p.Gly665Ser)
(het)
c.35delG (p.Gly12fs*2) (hom)
c.1054delG (p.Gly352Val*2)
(het)
c.6187C4T (p.Pro2063Ser)
(hom)
c.1118C4A (p.Thr373Lys)
(het)/ c.1205G4A
(p.Arg402Gln) (het)
c.307G4A (p.Val103Ile) (het)
c.2317G4A (p.Gly773Arg)
(het)

c.1096-11_1109del (p?) (het)

c.6947A4C (p.Gln2316Pro)
(het)
c.1760C4T (p.Thr587Met)
(het)
c.919G4T (p.Ala307Ser)
(hom)
c.3922-1G4C(p?) (het)

c.1117G4A (p.Gly373Arg)
(het)

c.847G4A (p.Val283Met) (het)
c.824_825del
(p.Cys276Trpfs*15) (hom)
c.1201A4T (p.Arg401*) (hom)

c.5723dupC
(p.Thr1909Asnfs*164) (het)
c.751A4C (p.Ile251Leu) (het)
c.364del (p.Glu122Asnfs*21)
(het)
c.756_757del (p.Arg253Ile*6)
(hom)
c.3021+1G4C (p?) (het)

Genomic variant (zygosity)

DN
MA/P

MA/P

DN

MA/P

MA/P
MA/P

N/A
DN

MA/P

MA/P

MA/P
P

P

DN
DN

DN

N/A

MA/P

N/A

DN

DN

MA/P

DN
MA/P

DN

MA/P

MA
N/A

N/A

Origina

Category 1. Nicolaides–Baraitser syndrome.
Category 2. Cutis laxa, type IIIA. Molecular diagnosis explains aetiology of similar fatal disease in sibling and enables counselling regarding recurrence
risks as well as deﬁnitive prenatal diagnosis.

Complex phenotype with two genetic disorders. Category 1. Pathogenic ATP1A3 variant associated with CAPOS Syndrome explains episodic hypotonia
and regression history. Patient also has pathogenic 2p16.3 337-kb deletion overlapping NRXN1 gene associated with global developmental delay and
Autism Spectrum disorder (Table 2).
Category 2. Pontocerebellar hypoplasia, type 2E. Older sibling with same clinical features, passed away at age 6 years, also diagnosed with the same
disease afterwards. Followed in the metabolic genetics clinic for symptomatic treatment.

Category 1. MRI diagnosis of COL4A1-related disorder conﬁrmed with sequence testing. Recommendations for surveillance by neurologist for disease
related complications including neurological, ocular, cardiac, renal and Raynaud's phenomena. Also requires aggressive hypertension management to
avoid strokes.
Category 3. Novel protein losing enteropathy disorder.
Complex phenotype with two related genetic disorders. Category 2. NGLY1—Congenital disorder of glycosylation, type Iv. Category 1. COG5—
Congenital disorder of glycosylation, type III.

Category 1. Query Axenfeld–Rieger syndrome but found to have SHORT syndrome. Father is also clinically affected and variant is paternally inherited.
Recommended screening for diabetes and glaucoma based on the diagnosis of SHORT syndrome.
Partial genetic diagnosis. Category 1. Complex phenotype with autosomal recessive hearing loss caused by GJB2 variant.
Complex phenotype with two genetic disorders. Category 1. Paternally inherited CCM2 pathogenic variant related to Cerebral cavernous malformation
(CCM) diagnosis. Potential pharmacotherapy interventions for CCM. Patient also has 8q22.1 de novo 1.16-Mb deletion (Table 2)
Partial genetic diagnosis. Category 1. Initially diagnosed with acquired Von Willebrand by haematology. However, molecular ﬁndings consistent with a
genetic aetiology.
Complex phenotype with two related genetic disorders. Category 1. Oculocutaneous albinism type 1. Category 2. MC4R variant may be contribute to
obesity

Category 1. Query Marfan/Homocytinuria and NF type I but found to have Sotos Syndrome. Referral to appropriate specialists for management of
learning disability/speech delays, behaviour problems, cardiac abnormalities, renal anomalies, scoliosis, seizures. No intervention if MRI shows
ventricular dilatation without raised intracranial pressure.
Category 1. Noonan Syndrome-like disorder with or without juvenile myelomonocytic leukaemia. Recommendation includes continued surveillance for
leukaemia.
Category 2. Autosomal dominant mental retardation 17.
Category 2. Query Robinow syndrome but found to have Mental retardation autosomal dominant 23.

Partial genetic diagnosis. Category 1. Multiple Exostoses Type 2. Radiographs conﬁm multiple exostoses consistent with EXT variant. Need surveillance
for increased cancer risk, and monitoring of exostoses growth.
Category 1. Pontocerebellar Hypoplasia Type 2A.

Category 2. Query extrapyramidal cerebral palsy but found to have congenital disorder of deglycosylation. Initiated screening for hepatic dysfunction
based on the diagnosis of NGLY1 deﬁciency.
Category 2. Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome-1 (MPPH). No change in management for the patient as she was
outside of the age range of proposed screening recommendations for MPPH at the time of diagnosis. However, same mutation identiﬁed in her sibling
who is now undergoing quarterly ultrasound surveillance for Wilms tumour. Germline mosacism suspected.
Category 1. Early infantile epileptic encephalopathy 5.

Category 1. KAT6B-related disorder. Recommendation of yearly evaluations of developmental progress, contractures and/or scoliosis by an
orthopaedist, ophthalmologic problems such as amblyopia (in SBBYSS), thyroid function tests, heart defects, and kidneys if hydronephrosis and/or
multiple renal cysts are present.
Category 2. Type C brachydactyly.
Category 2. Neurodegeneration with brain iron accumulation-1 (NBIA1).

Category 2. Query RASopathy but found to have Alazami Syndrome.

Partial genetic diagnosis. Category 2. Variant potentially related to obesity in proband. Mother also carries variant and has history of obesity.
Category 1. Referred for possible Noonan–Costello, found to have Cofﬁn–Siris syndrome.

Category 1. Rubinstein–Taybi Syndrome 2.

Diagnosis and managementb

Abbreviations: AD, autosomal dominant; AR, autosomal recessive; DN, de novo; F, female; IP, inheritance pattern; M, male; MA, maternal; N/A, not available; P, paternal.
a
Origin of Transmission: DN, P, MA and N/A.
b
All ﬁndings were relevant to Genetic counselling and were further split into categories based on clinical management: Category 1 (Disease-speciﬁc published management guidelines); Category 2 (Management based on case reports or
known function of genes); and Category 3 (No management change).

Sex

Clinically signiﬁcant sequence-level variants identiﬁed by whole-genome sequencing

Case
ID

Table 3.
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Table 4.

Medically actionable secondary ﬁndings

Case ID Sex Gene
1003
1027a
1040b

F
F
M

1063
1067

F
M

1078c

M

1091

M

IP

Genomic Variant (Zygosity)

Diagnosis

FBN1
AD
c.3509G4A p.Arg1170His (het) Marfan syndrome
COL3A1 AD
c.812G4A p.Arg271Gln (het) Ehlers-Danlos syndrome, type III; Ehlers-Danlos syndrome type IV
SCN5A AD/AR c.5239G4A p.Val1747Met (het) Brugada syndrome 1; Cardiomyopathy, dilated, 1E; Heart block, nonprogressive;
Heart block, progressive, type IA; Long QT syndrome-3; Sick sinus syndrome 1;
Ventricular ﬁbrillation, familial, 1
KCNH2 AD
c.3278C4T p.Pro1093Leu (het) Long QT syndrome; Short QT syndrome
SCN5A AD/AR c.5336C4T p.Thr1779Met (het) Brugada syndrome 1; Cardiomyopathy, dilated, 1E; Heart block, nonprogressive;
Heart block, progressive, type IA; Long QT syndrome-3; Sick sinus syndrome 1;
Ventricular ﬁbrillation, familial, 1
RYR2
AD
c.3320C4T p.Thr1107Met (het) Arrhythmogenic right ventricular dysplasia 2; Ventricular tachycardia,
catecholaminergic polymorphic
DSG2
AD
c.2434G4A p.Gly812Ser (het) Arrhythmogenic right ventricular dysplasia 10; Cardiomyopathy, dilated, 1BB

Abbreviations: AD, autosomal dominant; AR, autosomal recessive; F, female; IP, inheritance pattern; M, male.
a
A 894 kb (Chr16:15,507,164–16,400,833) pathogenic deletion was also detected in this patient (Table 2).
b
Partial diagnosis of Multiple Exostoses Type 2 (Table 3).
c
Diagnosis Oculocutaneous albinism type 1 (Table 3).

17 cases were negative for a diagnosis found through WGS,
including 11 panel tests, highlighting the limitation of using a
hypothesis-driven approach for this cohort. In the majority of
these cases, the causative gene was not included in the panel
testing; however, in one case, clinical panel testing failed to detect
a large 25-bp pathogenic indel in CBL that was detected through
WGS (Supplementary Figure 6 and Case 1050 in Supplementary
Table 8). In two cases, targeted genetic tests led to a clinical
diagnosis that could not be detected by WGS in the current study
design, including microsatellite analysis of parents and offspring
for UPD14 (heterodisomy) and a methylation test for Russell–Silver
syndrome (RSS).
DISCUSSION
Here we provide data that show WGS exceeds other technology
platforms in ability to detect genetic variants involved in
childhood disease. Speciﬁcally, in our design we achieved a
diagnostic yield of 34% when testing an unselected paediatric
population that was undergoing CMA as the current standard ﬁrsttier genetic test followed by traditional gene/panel testing
protocols. These results indicate WGS provides a fourfold increase
in molecular diagnosis over CMA alone (8%) and a greater than
twofold increase when all genetic testing protocols (410 tests in
some cases) are considered (13%).
The cohort we investigated was clinically heterogeneous with
~ 57% presenting with developmental delay as a primary clinical
feature. Consistent with previous data,8,9,25 the majority (63%) of
our sequence-level diagnoses were autosomal dominant. Combining CNVs and SNVs, just under half (14/34) of the diagnoses were
de novo mutations giving a minimum overall spontaneous
mutation rate of 14%. For autosomal recessive transmission, we
conﬁrmed molecular diagnoses from compound heterozygous
variants in only 2/100 patients, which is less than reported
previously8,9,25 and may be reﬂective of our study design in only
sequencing the proband. The majority of our AR diagnoses arose
from homozygous variants from consanguineous unions (reported
in 8% of cases in this cohort). Similar to other studies,8,9 4% of
cases had more than one locus involved, contributing to a
complex phenotype including two individuals with a pathogenic
CNV and SNV. In an additional ﬁve cases, a pathogenic variant was
found that only accounted for part of the phenotype, indicating
that upwards of 9% of individuals in this cohort may have more
than one genetic disorder (see Tables 2 and 3).
Our results demonstrate that the increased diagnostic utility of
WGS can have a signiﬁcant impact on clinical care and

management that goes beyond genetic counselling (Tables 2
and 3). Speciﬁcally, the rapid diagnosis of mutations in the CBL
gene in patient 1050 has important implications for the
surveillance of juvenile myelomonocytic leukaemia, which is
critical for patient management and survival. In the case of
patient 1049, the clinical phenotype was suggestive of a
connective tissue disorder with additional features suggestive of
NF1. However, WGS revealed a diagnosis of Sotos syndrome,
which subsequently changed clinical management of the patient
as the disease trajectory and requirements for surveillance are
inherently different for this disorder. Similarly, detection and
conﬁrmation of mutations in genes such as PIK3R1, EXT2, PIK3R2,
NGLY1, KAT6B and COL4A1 provides indications for monitoring of
disease-speciﬁc secondary complications that ultimately lead to
improvement of the patients’ quality of life, and at times can have
a critical impact on survival.
One of the current challenges facing health care providers is
determining the most effective utilisation of CMA versus sequencing gene panels versus WES in patients with developmental
disorders and/or congenital anomalies. A recent study using a
comprehensive genotype-driven approach in children with developmental delay achieved a diagnostic yield of 31% using WES and
CMA.25 The physicians in our study ordered an average of three
genetic tests (CMA plus two targeted genetic tests) per patient
guided by clinical features, which yielded a diagnostic rate half of
that achieved by WGS. Importantly, hypothesis-free WGS signiﬁcantly outperformed targeted testing of candidate genes in our
cohort: in 17/22 cases, the diagnostic sequence-level variant found
by WGS was not in a gene targeted by hypothesis-driven testing.
The number of prior genetic investigations for the illustrative
cases (Supplementary Table 8) ranged between three and six tests
at a total cost of $3,325–5,280 and would be largely representative
of this type of cohort seen at our hospital. Estimates of others have
shown even higher costs of negative testing ($19,100) in similar
cohorts and have demonstrated the cost of using genomic
sequencing to be ~ $3,000 per individual.26 Although full
economic evaluations are required, our data align with previous
studies where WGS enabled the use of a single diagnostic test in a
heterogeneous clinical cohort. In turn, this approach is likely to
reduce the number of genetic investigations and potentially the
time to diagnosis, ultimately acting as a more cost effective
approach.26,27
Although our study design was prospective, there are several
factors that may have inﬂuenced our estimation of the diagnostic
yield of WGS. The diagnostic laboratory at The Hospital for Sick
Children (Toronto, ON, Canada) receives ~ 600 CMA requests from
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Figure 1. Overview of study design comparing the diagnostic yield of whole-genome sequencing compared with standard of care genetic
testing. CMA, chromosomal microarray analysis; SNV, single-nucleotide variant; CNV, copy-number variant; HPO, Human Phenotype Ontology;
Dx, diagnostic.

clinical genetics per year and typically achieves a diagnostic yield
of 12% (95% CI 9.6–14.9%). The yield of CMA in the current study
was slightly lower (8%) than typically observed, but was similar in
those individuals that were approached and declined WGS. For
the 101 families who were approached and declined participation
there were two predominant reasons. First, ~ 35% of families were
uncomfortable with secondary ﬁndings as it pertains to obtaining
life or employment insurance as Canada does not currently have a
nondiscrimination law. Second, 35% of individuals declined since
they felt overwhelmed with the current medical complexity of
their child with most of these patients stemming from the NICU
population. Although there is a chance that our cohort had an
ascertainment bias, enrolment demographics indicate that this
cohort is typical of those submitted for CMA through clinical
genetics over the same timeframe.
One of the unique aspects in our study was the direct
interaction with the referring clinician to adjudicate whether
prioritised variants were medically relevant. This type of iterative
genotype–phenotype comparison is valuable in the interpretation
of a genome but is not amenable to large-scale implementation of
WGS diagnostic testing that would be done at a reference
laboratory. However, the phenotypic description submitted by the
referring physician via PhenoTips (www.phenotips.org) was
sufﬁcient to conﬁdently identify the clinically signiﬁcant variants
in the vast majority of diagnoses, without the need for further
consultation with the physician. We estimate that approximately
two diagnostic variants beneﬁted from direct clinician consultation after the genomic data were analysed.
In addition, our design did not allow the prioritisation of de
novo variants since we did not perform WGS on parents. WESbased studies have shown that the diagnostic yield is higher using
a trio design.9,18 Similarly, although WGS allows the detection of
npj Genomic Medicine (2016) 15012

large stretches of homozygosity due to uniparental isodisomy, we
would need parental genotypes to detect heterodisomy (e.g.,
UPD14 in case 1068). Moreover, our analysis was restricted mainly
to exonic variants due to the inability to clinically interpret the
majority of intronic and intergenic variants. The impact of
common risk variants will also need to be considered as methods
for complex statistical modelling improve. Finally, we did not
detect any pathogenic CNVs beyond the resolution of CMA that
led to a diagnosis in our cohort, but did ﬁnd some individuals to
be carriers of deletions affecting genes associated with autosomal
recessive disorders (Supplementary Table 9).
Genetics have long been known to have a major role in child
health. McCandless et al.3 found that, taken together, rare genetic
variants and common genetic factors signiﬁcantly contributed to
the illnesses of 71% of hospitalised children. However, our ability
to achieve molecular diagnoses for children with genetic disorders
has historically been quite limited. Our results indicate that WGS
can now be deployed advantageously as a ﬁrst-tier molecular test
in those individuals with developmental delay and/or congenital
abnormalities, as we identiﬁed medically actionable diagnostic
variants and secondary variants in 38% of children undergoing
clinical CMA, and achieved a diagnosis in one-third of the children.
As comparison datasets increase in size and methods for
annotating the vast non-genic segment (99%) of the genome
improve, so will the utility of WGS in diagnosis, management and
surveillance of paediatric genetic conditions.
MATERIALS AND METHODS
Patient selection/study cohort and phenotype collection
We developed a workﬂow to recruit patients and test the diagnostic utility
of WGS in the routine clinical care of children and their families (Figure 1).
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Patients were recruited in a prospective manner from the Division of
Clinical and Metabolic Genetics at Hospital for Sick Children over a
9-month period (September 2013 to May 2014). Patients and their parents
were eligible to participate in the study if the patient met standard clinical
criteria for CMA analysis. This included children with two or more structural
malformations (major or minor); or unexplained developmental delay/
intellectual disability with or without additional clinical features. We also
required both parents be available for testing and due to the complexity of
the tests, that both parents were ﬂuent in English. DNA was extracted from
peripheral blood. This study was approved by the Research Ethics Board at
The Hospital for Sick Children and informed consent was obtained from all
participants.

Phenotype collection
We used PhenoTips28 (www.phenotips.org) to capture and record
phenotypic data after thorough examination by a clinical geneticist.
PhenoTips is an open source software program for collecting and analysing
phenotypic information for patients with genetic disorders. The software
combines an easy-to-use web browser interface with a standardized
database back end. Phenotypic information is collected and represented
using the Human Phenotype Ontology.29 Collected data include
demographics, medical history, family history, physical and laboratory
measurements, physical ﬁndings, and additional notes. Importantly,
phenotypic data for each patient were accessible in a standardized format
by laboratory geneticists and clinical geneticists performing variant
interpretation.

Chromosomal microarray analysis

association,29,43,44 MGI (http://www.informatics.jax.org/). Data set and
software versions are listed in the Supplementary Information.

Diagnostic algorithm and variant interpretation
We developed a pipeline to systematically prioritise clinically signiﬁcant
variants (see Supplementary Figure 1). We ﬁrst deﬁned a list of high
quality, rare variants ( o5% population frequency) that were exonic (genes
or ncRNA) or predicted to impact splicing. To aid in prioritisation variants
were categorized into ordered tiers based on: (i) sequence quality; (ii) allele
frequency; (iii) conservation and predicted impact on coding and noncoding sequence; and (iv) human disease and mouse abnormal phenotype
association. Variants were further sorted based on: (v) their zygosity and
gene mode of inheritance; and (vi) HGMD and ClinVar pathogenicity
classiﬁcation, reﬂecting implication in human genetic disorders documented in the literature (see Supplementary Information for detailed
deﬁnitions). The ACMG recommendations for clinical interpretation of
sequence variants23 were used to classify variants as pathogenic or likely
pathogenic. Candidate diagnostic variants were selected based on their
likely pathogenicity and explanatory power. Variants deemed diagnostic
by both the assessment team and the referring physician were conﬁrmed
in the proband, and followed up in parental samples by Sanger
sequencing.

Secondary variants
The pipeline described above allowed for the identiﬁcation of clinically
relevant variants not related to the primary indication. The analysis was the
same as for primary variants except that we focused on variants with the
highest predicted impact (‘LoF’, criterion iii) and those reported to be
pathogenic by HGMD or ClinVar (criterion vi). This included UTR, intronic
and intergenic variants, for which impact prediction is more difﬁcult.
Finally we limited reporting of secondary variants to the 56 genes named
in the 2013 ACMG guidelines on return of incidental ﬁndings.20

All cases underwent chromosomal microarray analysis (CMA) using the
4 × 180 K Cytosure ISCA v2 oligonucleotide microarray platform (Oxford
Gene Technology, Oxford, UK) as part of diagnostic service in the CLIA
certiﬁed laboratory at The Hospital for Sick Children. Microarray experiments were performed according to the manufacturer’s instructions.
Brieﬂy, DNA from the proband and pooled same-sex reference DNA
(Promega, Madison, WI, USA) were labelled with Cy3-dCTP and Cy5-dCTP,
respectively, and were hybridised to the array slide. The arrays were then
scanned using the Agilent G2505B microarray scanner and resulting data
analysed using the CytoSure Interpret Software version 3.4.3 from Oxford
Gene Technology (Begbroke, Oxfordshire, UK). CNVs on chromosome Y
were removed from the analysis. Identiﬁed CNVs were classiﬁed according
to ACMG22 guidelines and pathogenic and variant-of-unknown-signiﬁcance—likely pathogenic were considered as clinically signiﬁcant.

Analysts (molecular or clinical geneticists) examined variant ﬁles and
prioritized clinically relevant variants using sequence quality, allele
frequency, conservation and predicted impact on coding and noncoding sequence, presence in Clinvar or HGMD, zygosity and genic mode
of inheritance, and relevance to clinical phenotype provided. Candidate
pathogenic variants that were interpreted to be clinically relevant to the
primary or secondary phenotype were discussed with the referring
clinician and designated diagnostic by consensus.

Whole-genome sequencing

Conﬁrmation of sequence-level variants

Genomic DNA was sent to Complete Genomics (Mountain View, CA, USA)
for WGS as described previously.30 Raw sequence reads were reassembled
against a reference genome (GRCh37) and variant calling was completed
using Complete Genomics assembly pipeline 2.4 as previously described.31
This method generates a fragment of ~ 400 bp that is covered by a set of 8
reads totalling 70 bp sequenced. All samples passed internal Complete
Genomics sample checks. Sequence results were received on hard drives
and consisted of raw data plus variant calls in the form of (i) SNV and small
indels, (ii) structural variants (based on abnormal junction and discordant
mate-pair clusters, with size typically 50–75,000 bp), (iii) CNVs (based on
normalised sequencing coverage, with size typically 42,000 bp).

Variants that were deemed to be potentially diagnostic after consultation
with the clinician were conﬁrmed with Sanger sequencing in a CLIA/CAP
laboratory and a clinical report was generated. Sanger sequencing
attempted for 58 variants, of which 51 of high quality (tier 2 analytic
quality) had 100% conﬁrmation rate. Parents and siblings were tested to
conﬁrm segregation for the reported pathogenic changes, or rule variants
out if they did not segregate.

Annotation of sequence-level variants (SNVs and indels)
Complete Genomics (Mountain View, CA, USA) masterVar ﬁles were
annotated using a custom pipeline based on Annovar,32 RefSeq gene
models (downloaded from UCSC 2013 February 12), and publicly available
as well as internal databases for allele frequency (1000 Genomes,33 NHLBIESP,34 ExAC browser (Exome Aggregation Consortium (ExAC), Cambridge,
MA, USA (URL: http://exac.broadinstitute.org) January 2015), Internal
Complete Genomics control databases public genomes and Wellderly
population, genomic conservation (UCSC PhyloP and phastCons for
placental mammals and 100 vertebrates35) and variant impact predictors
(SIFT,36 PolyPhen2,37 Mutation Assessor,38 CADD39). We also expanded the
annotation of non-coding regulatory sequence through implementation of
splicing exon inclusion/exclusion predictions.40 Finally we annotated
variants with those reported previously in disease (ClinVar,41 HGMD42)
and genes reported to have abnormal mouse and human phenotype

Clinical interpretation of variants

WGS CNV detection and annotation
CNVs from Complete Genomics are detected through both read depth and
paired-end sequencing and provided in cnvSegmentsDiploidBeta and
highConﬁdenceSVEventsBeta ﬁles, respectively. The read depth method is
based on deviation from a diploid baseline reference genome and uses
2 kb, GC-corrected windows with a hidden Markov model caller. The
paired-end method by Complete Genomics employs junction detections
on uniquely mapped discordant mate-pairs and can detect CNVs below
2 kb. CNVs were extracted from the cnvSegmentsDiploidBeta by parsing
out segments not equal to diploid of 2 and by excluding the hypervariable
regions. From the highConﬁdenceSVEventsBeta ﬁle we only extracted
deletions and tandem duplications supported by at least 20 mate-pair
reads based on previous sensitivity and speciﬁcity calculations24). CNVs
from Chromosome Y were removed. We annotated and analysed the CNV
and SV ﬁles separately. Copy number gains and losses from WGS were
annotated for frequency based on 50% reciprocal overlap with CNVs called
in WGS control samples, and overlap with CNVs from the Database of
Genomic Variants (November 2010 and March 2013 versions);45 CNVs were
also annotated for overlapping gene transcripts and exons (RefSeq,
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downloaded March 2013). Rare CNVs from either ﬁle were examined in the
context of case phenotype and classiﬁed using standard criteria.22

WGS comparison with CMA
The advantage of WGS over CMA for detecting CNVs is the ability to detect
small CNVs, offer precise breakpoint resolution, determine the location and
orientation of duplicated sequences, and ﬁnd allele speciﬁc copy-number
changes.17,24 Although WGS detects a signiﬁcantly larger number of
unbalanced changes compared to CMA, one of the most important
questions regarding replacement of CMA with WGS in the diagnostic
setting is that of accuracy. Our previous work has shown high
reproducibility of CNV detection using the WGS read depth method
(94%) with lower reproducibility with the paired-end method (73%).24 As
the CNV generated from the WGS read depth method is more comparable
to CMA in terms of the size detection range we determined the
concordance for these methods. Previous studies and our own experience
have shown that CMA lacks speciﬁcity and sensitivity in polymorphic
regions overlapping with segmental duplications and affect CNV
concordance between different platforms.46 To minimise these, we
excluded CNVs showing at least 70% overlap with segmental duplications
or having a frequency of least 3% in either data set. These criteria yielded
165 rare CNVs from the CMA, with 84% detected by the read depth
method of WGS. Further analysis of the 26 CNVs not detected by WGS
showed that the majority were in regions overlapped by segmental
duplications and were labelled as ‘hypervariable’ in the WGS data.
Importantly, none of these variants were identiﬁed as being clinically
relevant. We examined the breakpoint concordance by comparing the
difference between the CMA proximal and distal breakpoint (within probe
error) to the WGS. Breakpoint analyses of the 139 concordant CNVs
showed ~ 78% fall between the minimum and maximum boundaries of
breakpoints deﬁned by the clinical microarray, and 87% are within 10 kb of
these boundaries (Supplementary Figure 9).

WGS diagnostic yield compared to standard clinical testing
We compared the diagnostic yield of WGS to both CMA and CMA
combined with targeted gene testing. Statistical differences were
calculated using a χ2 proportion test.
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